The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of quantitative p95HER2 and HER2 protein expression with pathologic complete response (pCR) in HER2-positive breast cancer patients (pts) treated with neoadjuvant (NEO) trastuzumab-containing therapy.
Jose Caetano Villasboas
No relevant relationships to disclose
Judith Hurley
No relevant relationships to disclose
Jodi Marie Weidler
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Agnes Paquet
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Carmen Gomez Fernandez
No relevant relationships to disclose
Maureen Cioffi Lavina
No relevant relationships to disclose
Jeff Sperinde
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Ahmed Chenna
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Mojgan Haddad
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Yolanda Lie
Employment or Leadership Position - Monogram Biosciences
John William Winslow
Employment or Leadership Position - Monogram Biosciences
Weidong Huang
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Christos J. Petropoulos
Employment or Leadership Position - Monogram Biosciences
Stock Ownership - LabCorp
Mark D. Pegram
No relevant relationships to disclose